@article{139e296b00e34ac581a1c001c8599c3f,
title = "Chronic kidney disease and arrhythmias: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference",
keywords = "arrhythmia, atrial fibrillation, chronic kidney disease, stroke, sudden cardiac death",
author = "Christoph Wanner and Herzog, \{Charles A.\} and Turakhia, \{Mintu P.\} and Blankestijn, \{Peter J.\} and Carrero, \{Juan Jesus\} and Clase, \{Catherine M.\} and Rajat Deo and Kasner, \{Scott E.\} and Passman, \{Rod S.\} and Roberto Pecoits-Filho and Holger Reinecke and Shroff, \{Gautam R.\} and Wojciech Zareba and Michael Cheung and Wheeler, \{David C.\} and Winkelmayer, \{Wolfgang C.\}",
note = "Funding Information: CW declared having received consultancy fees from Boehringer Ingelheim, GlaxoSmithKline, and Sanofi Genzyme; speaker honorarium from Boehringer Ingelheim, Merck Sharpe \& Dohme, and Sanofi Genzyme; and research support from Sanofi Genzyme. CAH declared having received consultancy fees from AbbVie, FibroGen, KBP Biosciences, OxThera, and Relypsa; equity ownership/stock options on Boston Scientific, Bristol-Myers Squibb, General Electric, Johnson \& Johnson, and Merck; and research support from Amgen, National Institutes of Health, Relypsa, and Zoll. CAH also expects future consultancy roles from AstraZeneca, Boehringer Ingelheim, Corvidia, and Sanifit. MPT declared having received consultancy fees from Abbott, iBeat, iRhythm, Medtronic, and Precision Health Economics; equity ownership/stock options on AliveCor and iBeat; speaker honorarium from Abbott and Medtronic; and research support from American Heart Association, Apple, Cardiva Medical, and Veterans Health Administration. ",
year = "2018",
month = aug,
day = "1",
doi = "10.1016/j.kint.2018.05.005",
language = "English",
volume = "94",
pages = "231--234",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Elsevier",
number = "2",
}